Goal-Directed Sedation in Mechanically Ventilated Infants and Children

Recruiting now · Phase 3

Conditions studied: Delirium, Critical Illness, Sedation Complication, Executive Dysfunction, Post Traumatic Stress Disorder

In brief

Ventilated pediatric patients are frequently over-sedated and the majority suffer from delirium, a form of acute brain dysfunction that is an independent predictor of increased risk of dying, length of stay, and costs. Universally prescribed sedative medications-the GABA-ergic benzodiazepines-worsen this brain organ dysfunction and independently prolong duration of ventilation and ICU stay, and the available alternative sedation regimen using dexmedetomidine, an alpha-2 agonist, has been shown to be superior to benzodiazepines in adults, and may mechanistically impact outcomes through positive effects on innate immunity, bacterial clearance, apoptosis, cognition and delirium. The mini-MENDS trial will compare dexmedetomidine and midazolam, and determine the best sedative medication to reduce delirium and improve duration of ventilation, and functional, psychiatric, and cognitive recovery in our most vulnerable patients-survivors of pediatric critical illness.

Key facts

Study ID

NCT04801589

Run by

Vanderbilt University Medical Center

People needed

372

Starts

2021-05-10

Expected to finish

2026-09-16

Last updated by the study team

2025-09-29

Who can join

Age: 1 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients will be eligible for enrollment if they are 1) aged 44 weeks post-menstrual age and up to 11 years, 2) planned admission to the pediatric ICU at Monroe Carell Jr. Children's Hospital at Vanderbilt (MCJCHV), and 3) requiring mechanical ventilation (MV) and sedation. Pre-pubescent children (<11 years) are typically different from older children who often behave physiologically more similar to adults. Pre-pubescent children are more likely to be admitted to the PICU and are undergoing a steeper curve of neurocognitive maturation. Therefore, these patients may be at greatest risk for worse brain dysfunction.
• Exclusion Criteria: Patients will be excluded (i.e., not approached for consent) if any one is present:
• Receiving continuous sedation for > 72 hours prior to screening.
• Rapidly resolving respiratory failure at screening, with planned immediate liberation from MV.
• Severe developmental delay at baseline defined as a score of ≥ 4 (severe disability) on the Pediatric Cerebral Performance Category (PCPC) Scale, referencing cognitive status prior to critical illness.
• Clinically significant 2nd or 3rd degree heart block or bradycardia < 60 beats per minute.
• Benzodiazepine dependency with ongoing medical requirement of continuous benzodiazepine (infusion).
• Inability to co-enroll with another study.
• Expected death or care plan for withdrawal of support measures within 24 hours of enrollment.
• Bilateral vision loss.
• Deafness that will preclude delirium evaluation.
• Inability to understand English that will preclude delirium evaluation. The inability to understand English in verbal participants will not result in exclusion when the research staff is proficient and/or translation services are actively available in that particular language.
• Documented allergy to either dexmedetomidine or midazolam.
• Medical requirement of continuous (infusion) neuromuscular blockade administration that is planned ongoing for at least 48 hours at time of screening.
• Inability to start the informed consent process within the 72 hours from the time that all inclusion criteria were met (possible reasons):
• Attending physician refusal
• 72-hour period of eligibility was exceeded before the patient was enrolled
• Legal Authorized Decision Maker (e.g. legal guardian/power of attorney) refusal
• Legal Authorized Decision Maker (e.g. legal guardian/power of attorney) unavailable
• Legal Authorized Decision Maker (e.g. legal guardian/power of attorney) is non-English speaking and available research staff is not proficient and/or translation services are not available in that particular language.
• Adjusted dosing weight is > 50 kg at time of screening.

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.